Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

医学 安慰剂 2型糖尿病 中止 体质指数 人口 内科学 减肥 超重 肥胖 养生 糖尿病 意向治疗分析 随机对照试验 临床终点 物理疗法 内分泌学 病理 替代医学 环境卫生
作者
W. Timothy Garvey,Juan P. Frías,Ania M. Jastreboff,Carel W. le Roux,Naveed Sattar,Diego Aizenberg,Huzhang Mao,Shuyu Zhang,Nadia N. Ahmad,Mathijs C. Bunck,Imane Benabbad,X. Zhang,Franklin Ábalos,Federico C. Pérez Manghi,Cesar Javier Zaidman,Marisa L. Vico,Diego Aizenberg,P. Costanzo,L. Serra,Ignacio MacKinnon
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10402): 613-626 被引量:337
标识
DOI:10.1016/s0140-6736(23)01200-x
摘要

Weight reduction is essential for improving health outcomes in people with obesity and type 2 diabetes. We assessed the efficacy and safety of tirzepatide, a glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, versus placebo, for weight management in people living with obesity and type 2 diabetes.This phase 3, double-blind, randomised, placebo-controlled trial was conducted in seven countries. Adults (aged ≥18 years) with a body-mass index (BMI) of 27 kg/m2 or higher and glycated haemoglobin (HbA1c) of 7-10% (53-86 mmol/mol) were randomly assigned (1:1:1), using a computer-generated random sequence via a validated interactive web-response system, to receive either once-weekly, subcutaneous tirzepatide (10 mg or 15 mg) or placebo for 72 weeks. All participants, investigators, and the sponsor were masked to treatment assignment. Coprimary endpoints were the percent change in bodyweight from baseline and bodyweight reduction of 5% or higher. The treatment-regimen estimand assessed effects regardless of treatment discontinuation or initiation of antihyperglycaemic rescue therapy. Efficacy and safety endpoints were analysed with data from all randomly assigned participants (intention-to-treat population). This trial is registered with ClinicalTrials.gov, NCT04657003.Between March 29, 2021, and April 10, 2023, of 1514 adults assessed for eligibility, 938 (mean age 54·2 years [SD 10·6], 476 [51%] were female, 710 [76%] were White, and 561 [60%] were Hispanic or Latino) were randomly assigned and received at least one dose of tirzepatide 10 mg (n=312), tirzepatide 15 mg (n=311), or placebo (n=315). Baseline mean bodyweight was 100·7 kg (SD 21·1), BMI 36·1 kg/m2 (SD 6·6), and HbA1c 8·02% (SD 0·89; 64·1 mmol/mol [SD 9·7]). Least-squares mean change in bodyweight at week 72 with tirzepatide 10 mg and 15 mg was -12·8% (SE 0·6) and -14·7% (0·5), respectively, and -3·2% (0·5) with placebo, resulting in estimated treatment differences versus placebo of -9·6% percentage points (95% CI -11·1 to -8·1) with tirzepatide 10 mg and -11·6% percentage points (-13·0 to -10·1) with tirzepatide 15 mg (all p<0·0001). More participants treated with tirzepatide versus placebo met bodyweight reduction thresholds of 5% or higher (79-83% vs 32%). The most frequent adverse events with tirzepatide were gastrointestinal-related, including nausea, diarrhoea, and vomiting and were mostly mild to moderate in severity, with few events leading to treatment discontinuation (<5%). Serious adverse events were reported by 68 (7%) participants overall and two deaths occurred in the tirzepatide 10 mg group, but deaths were not considered to be related to the study treatment by the investigator.In this 72-week trial in adults living with obesity and type 2 diabetes, once-weekly tirzepatide 10 mg and 15 mg provided substantial and clinically meaningful reduction in bodyweight, with a safety profile that was similar to other incretin-based therapies for weight management.Eli Lilly and Company.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
缥缈剑愁发布了新的文献求助10
1秒前
CodeCraft应助圆蓬蓬采纳,获得10
1秒前
zhaoyuli完成签到,获得积分10
1秒前
啊啊发布了新的文献求助10
1秒前
1秒前
ZH发布了新的文献求助10
3秒前
研友_VZG7GZ应助Endeavor采纳,获得10
3秒前
warden完成签到 ,获得积分10
3秒前
科研通AI2S应助sisyphus_yy采纳,获得10
4秒前
施天问发布了新的文献求助10
4秒前
6秒前
Singularity应助内向寒云采纳,获得10
6秒前
dd完成签到 ,获得积分10
6秒前
7秒前
Miracle发布了新的文献求助10
8秒前
开花完成签到,获得积分10
8秒前
量子星尘发布了新的文献求助10
9秒前
10秒前
redking完成签到,获得积分10
10秒前
lingquanmeng完成签到,获得积分10
11秒前
11秒前
羽生发布了新的文献求助10
11秒前
隐形曼青应助miumiu采纳,获得10
12秒前
beckham发布了新的文献求助10
13秒前
施天问完成签到,获得积分10
14秒前
uu发布了新的文献求助10
14秒前
15秒前
15秒前
15秒前
小蘑菇应助Miracle采纳,获得10
15秒前
轩轩轩轩完成签到 ,获得积分10
16秒前
16秒前
17秒前
litao完成签到,获得积分10
18秒前
乐乐应助九千七采纳,获得10
20秒前
梁三柏应助makabaka采纳,获得10
20秒前
21秒前
21秒前
xyz发布了新的文献求助10
22秒前
25秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975755
求助须知:如何正确求助?哪些是违规求助? 3520108
关于积分的说明 11200829
捐赠科研通 3256492
什么是DOI,文献DOI怎么找? 1798298
邀请新用户注册赠送积分活动 877509
科研通“疑难数据库(出版商)”最低求助积分说明 806403